Markets Businessinsider
Published November 16, 2026
Clearmind Achieves Full Enrollment for Part C in CMND-100 Phase I/IIa Trial, Marking Key ...
Read the full story at Markets Businessinsider
(Nasdaq: CMND) (“Clearmind” or the “Company”), a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic -derived.
Surfaced by 2 Google Alerts
- Psychedelics
- Psychedelic press release